Master of Engineering in Biomedical Engineering
Being on the leading edge of research advances means you’ll think like a scientist, an engineer, an entrepreneur—all with technology in the forefront.
Research laboratories at WPI’s Life Sciences & Bioengineering Center at Gateway Park include a 124,600-square-foot space. These labs focus on non-invasive biomedical instrumentation design, signal processing, tissue biomechanics, biomaterials synthesis and characterization, myocardial regeneration, cell and molecular engineering, regenerative biosciences, and tissue engineering.
Classroom knowledge is applied directly to real-world problems as faculty and students work side-by-side in labs, always striving for the next innovation in regenerative medicine, drug discoveries, tissue remodeling, medical imaging, or physiological monitoring.
Successful collaborations with industry partners and significant funding for major research means our faculty and students have the resources to make discoveries that impact areas such as biomaterials and tissue engineering, biomechanics and mechanobiology, and bioinstrumentation and signal processing.
Faculty Profiles
Understanding the mechanisms by which mechanical forces regulate the development and healing of connective tissues and the pathogenesis of disease is becoming one of the foremost problems at the intersection of biomechanics and cell biology—it has spawned the field of mechanobiology. In our lab we use precisely engineered, two-dimensional and three-dimensional constructs as model systems to study the effects of external internal (cell-generated) forces on cell behavior, matrix biochemistry, and the biomechanics of soft tissues and biomaterials.
The overall objectives of my research are to develop clinically translatable tissue regeneration and drug delivery strategies, and three-dimensional, in vitro human disease models using biologically-derived biomaterials. We will utilize techniques from engineering, chemistry and biology to address these research areas, including chemical modifications to alter drug-material interactions, small molecule and macromolecule conjugates to direct cell fate, and multi-cellular tissue/disease systems for paracrine signaling and direct cell-cell interactions.
Glenn R. Gaudette, PhD, is a Professor of Biomedical Engineering at Worcester Polytechnic Institute. He received his PhD in Biomedical Engineering from SUNY – Stony Brook. He has over 75 publications, co-edited a book on Cardiovascular Regeneration, has 4 issued patents and founded a company based on the technology developed in his laboratory. His research, which is supported by the National Institutes of Health and the National Science Foundation, aims to develop a treatment for the millions of Americans suffering from myocardial infarction and other cardiovascular diseases.
The biomechanical mechanisms behind traumatic brain injury (TBI) have been an active research focus for more than 70 years. However, the field is still largely focused on impact kinematics or estimated brain responses in generic regions from single head impact to predict a binary brain injury status on a population basis. An important research focus in my lab is to integrate advanced neuroimaging into TBI biomechanics research to understand injuries to functionally important neural pathways. At the same time, we develop techniques to achieve near real-time response feedbacks.
The overall objective of my research is to create bioengineered scaffolds to enhance the regeneration of damaged tissues and organs. Specifically, my laboratory uses biomimetic design strategies and novel fabrication processes to develop three-dimensional constructs that emulate native tissue architecture and cellular microenvironments. We use these scaffolds to characterize the roles of extracellular matrix (ECM) cues and topographic features in modulating cellular functions, including adhesion, migration, proliferation, differentiation, and tissue remodeling.
My research focuses on combining bio-instructive biomaterials with cells to design 3D tissue-engineered platforms for regenerative medicine, disease modeling, improved predictability of therapeutic outcomes, and as translatable technologies for clinic and industry.